All In Biotech

Investigational drug · Phase 2

TG4050

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Squamous Cell Carcinoma of Head and Neck.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

2

Any phase or sponsor naming "TG4050"

First trial start

2019

Dec 12, 2019

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TG4050", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Squamous Cell Carcinoma of Head and Neck

Approved drugs for the same conditions: Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "TG4050" as an intervention, largest first.

All trials
  • TransgeneIndustry

    NCT04183166 · 80 participants · Start Dec 12, 2019 · Primary completion Dec 30, 2027

    Drug: TG4050 · For: Squamous Cell Carcinoma of Head and Neck

    Sites: Jacksonville, Florida; Bordeaux, France; Marseille, France · 14 sites in all

  • TransgeneIndustry

    NCT03839524 · 64 participants · Start Dec 9, 2019 · Primary completion Oct 8, 2024

    Drug: TG4050 · For: Ovarian Carcinoma; Fallopian Tube Cancer; Peritoneal Carcinoma

    Sites: Phoenix, Arizona; Jacksonville, Florida; Rochester, Minnesota · 6 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Squamous Cell Carcinoma of Head and Neck

  • SI-B001Phase 39 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck

  • IO102-IO103Phase 33 trials

    IO Biotech · Metastatic Melanoma, Unresectable Melanoma, Melanoma

  • SI-B003Phase 210 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck

  • GV20-0251Phase 23 trials

    GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum

  • ImzokitugBMS-986340Phase 22 trials

    Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer

  • DM005Phase 21 trial

    Doma Biopharmaceutical(Suzhou)Co., Ltd. · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma

  • EvalstotugBA3071Phase 21 trial

    BioAtla, Inc. · Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck, Recurrent Squamous Cell Carcinoma of the Head and Neck

  • TH9619Phase 21 trial

    One-carbon Therapeutics AB · Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.